<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Factors influencing KRAS test results in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens include: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, sample handling, slide preparation, techniques for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> enrichment, DNA preparation, assay design and sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated comparability and consistency of KRAS test results among five laboratories currently being used to determine KRAS mutation status of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> specimens in a large, multi-center observational study </plain></SENT>
<SENT sid="3" pm="."><plain>FINDINGS: Twenty formalin-fixed paraffin-embedded human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> samples from colon resections previously tested for KRAS mutations were selected based on mutation status (6 <z:mp ids='MP_0002169'>wild type</z:mp>, 8 codon 12 mutations, and 6 codon 13 mutations) </plain></SENT>
<SENT sid="4" pm="."><plain>We found good agreement across laboratories despite differences in mutation detection methods </plain></SENT>
<SENT sid="5" pm="."><plain>Eighteen of twenty samples (90%) were concordant across <z:hpo ids='HP_0000001'>all</z:hpo> five labs </plain></SENT>
<SENT sid="6" pm="."><plain>Discordant results are likely not due to laboratory error, but instead to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, contamination of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> sample with <z:mpath ids='MPATH_458'>normal</z:mpath> tissue, or analytic factors affecting assay sensitivity </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Our results indicate commercial and academic laboratories provide reliable results for the common KRAS gene mutations at codons 12 and 13 when an adequate percentage of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells is present in the sample </plain></SENT>
</text></document>